Victor Sandor
Director/Board Member at MERUS N.V.
Net worth: 261 969 $ as of 2024-03-30
Profile
Victor Sandor is an Independent Non-Executive Director at Merus NV, ADC Therapeutics SA, Prelude Therapeutics, Inc., Kymera Therapeutics, Inc., and Istari Oncology, Inc. He previously worked as the SVP-Global Clinical Development at Incyte Corp., Chief Medical Officer at Array BioPharma, Inc., and Chief Medical Officer-Oncology & VP at Biogen Idec, Inc. He holds a doctorate degree from McGill University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ADC THERAPEUTICS LTD
0.07% | 2024-01-31 | 58,345 ( 0.07% ) | 261 969 $ | 2024-03-30 |
MERUS N.V.
-.--% | 2023-06-07 | 0 ( -.--% ) | - $ | 2024-03-30 |
| 2023-06-15 | 0 ( -.--% ) | - $ | 2024-03-30 | |
| 2023-06-14 | 0 ( -.--% ) | - $ | 2024-03-30 |
Victor Sandor active positions
| Companies | Position | Start |
|---|---|---|
| MERUS N.V. | Director/Board Member | 2019-06-11 |
| ADC THERAPEUTICS SA | Director/Board Member | 2020-04-26 |
| PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 2020-04-30 |
| KYMERA THERAPEUTICS, INC. | Director/Board Member | 2022-11-02 |
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 2019-06-30 |
Former positions of Victor Sandor
| Companies | Position | End |
|---|---|---|
| INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 2019-08-31 |
| ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 2019-07-31 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 2014-08-31 |
Training of Victor Sandor
| McGill University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| MERUS N.V. | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Stock Market
- Insiders
- Victor Sandor
